Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Net Cash Flow (2020 - 2025)

Vivos Therapeutics' Net Cash Flow history spans 6 years, with the latest figure at -$1.0 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$1.0 million for Q4 2025, down 9072.73% from a year ago — trailing twelve months through Dec 2025 was -$15.7 million (down 440.52% YoY), and the annual figure for FY2025 was -$4.2 million, down 191.82%.
  • Net Cash Flow for Q4 2025 was -$1.0 million at Vivos Therapeutics, up from -$1.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $20.2 million in Q2 2021 to a low of -$9.4 million in Q2 2025.
  • The 5-year median for Net Cash Flow is -$3.0 million (2023), against an average of -$1.4 million.
  • The sharpest move saw Net Cash Flow surged 6475.83% in 2021, then plummeted 9072.73% in 2025.
  • Year by year, Net Cash Flow stood at -$4.5 million in 2021, then grew by 28.95% to -$3.2 million in 2022, then surged by 121.97% to $703000.0 in 2023, then plummeted by 101.56% to -$11000.0 in 2024, then plummeted by 9072.73% to -$1.0 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$1.0 million, -$1.4 million, and -$9.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.